GENEDIT
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.
GENEDIT
Industry:
Biotechnology Genetics Pharmaceutical Therapeutics
Founded:
2016-04-04
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.genedit.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
43.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Porton Advanced Solutions
Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Angel Round - GenEdit
Korea Investment Partners
Korea Investment Partners investment in Series A - GenEdit
KTB Network
KTB Network investment in Series A - GenEdit
IMM Investment
IMM Investment investment in Series A - GenEdit
Company K Partners
Company K Partners investment in Series A - GenEdit
Time Folio Asset Management
Time Folio Asset Management investment in Series A - GenEdit
Bow Capital
Bow Capital investment in Series A - GenEdit
Dayli Partners
Dayli Partners investment in Series A - GenEdit
Sequoia Capital
Sequoia Capital investment in Series A - GenEdit
SK Holdings
SK Holdings investment in Series A - GenEdit
Official Site Inspections
http://www.genedit.com Semrush global rank: 7.8 M Semrush visits lastest month: 437
Unable to get host informations!!!
More informations about "GenEdit"
GenEdit - Crunchbase Company Profile & Funding
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s …See details»
About - GenEdit
Mar 1, 2025 At GenEdit, we aim to overcome the existing limitations in genetic medicine so we can positively impact the lives of as many people as possible. Our Vision. Our co …See details»
GenEdit | Revolutionizing Genetic Medicines
We are advancing therapies enabled by our delivery platform, NanoGalaxy®. Delivery challenges have historically prevented genetic medicines from reaching their full potential to benefit patients.See details»
Genedit 2025 Company Profile: Valuation, Funding
When was Genedit founded? Genedit was founded in 2016. Where is Genedit headquartered? Genedit is headquartered in Brisbane, CA. What is the size of …See details»
Careers - GenEdit
GenEdit fosters an exciting and dynamic environment where we value impactful data and creative solutions to accelerate our progression from a platform technology to a pipeline of therapeutic candidates. We are seeking talented …See details»
GenEdit Company Overview, Contact Details & Competitors | LeadIQ
Jan 23, 2024 Key Hire: CSO Recently appointed Chief Scientific Officer, J. Rodrigo Mora, brings valuable expertise to GenEdit, enhancing the credibility of the organization and potentially …See details»
GenEdit Company Profile | Management and Employees List
GenEdit Profile and History. At GenEdit, our mission is to discover and develop innovative genetic medicines with targeted in vivo delivery. Our NanoGalaxy platform of non-viral, non-lipid …See details»
GenEdit: Contact Details, Revenue, Funding, Employees and …
GenEdit focuses on overcoming the delivery challenges of genetic medicines using its NanoGalaxy platform, which features a library of non-viral, non-lipid polymer nanoparticles. …See details»
GenEdit, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
A spotlight has been on nanomedicine following the success of lipid nanoparticle-based Covid-19 vaccines. In January 2024, Roche’s Genentech teamed up with biotech GenEdit to use the …See details»
GenEdit - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Pre Seed Round - GenEdit . …See details»
GenEdit - Contacts, Employees, Board Members, Advisors & Alumni
Organization. GenEdit . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. ... GenEdit has 8 board …See details»
GenEdit - Org Chart, Teams, Culture & Jobs - The Org
View GenEdit's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
GenEdit - VentureRadar
GenEdit’s mission is to discover and develop innovative genetic medicines with targeted in vivo delivery. The genetic medicine delivery methods available today limit the potential benefit to …See details»
GenEdit, Inc. | Intellectual Property & Industry Research Alliances
The GenEdit founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe …See details»
GenEdit Expands Leadership Team to Advance Targeted Genetic …
Sep 22, 2021 SOUTH SAN FRANCISCO, Calif., September 22, 2021 – GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo …See details»
GenEdit Company Profile: Overview and Full News Analysis
GenEdit, Inc. is a developer of genetic medicines that leverage its NanoGalaxy platform for tissue-selective delivery . Dr. Rodrigo Mora is an accomplished immunologist and research and …See details»
Company: GenEdit - CRISPR Medicine
GenEdit develops next-generation in vivo gene delivery systems. The company raised $26M in a Series A funding round in September 2021. The technology is based on non-lipid polymer …See details»
GenEdit - zoonop.com
GenEdit stands at the forefront of biotechnology innovation, with significant contributions to the field of genetic medicine delivery. The company's proprietary NanoGalaxy® platform presents …See details»
A Brief History of GenEdit – CBM - canvasbusinessmodel.com
Oct 2, 2024 [cbm_blg_rlnkng]In the ever-evolving field of genetic editing, GenEdit stands as a pioneering company at the forefront of innovation. Founded in 2015 by a team of brilliant …See details»
GenEdit Announces Multiyear Collaboration and License …
Jan 23, 2024 SOUTH SAN FRANCISCO, Calif., January 23, 2024 – GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy ® platform for tissue-selective delivery, …See details»